Horizon Therapeutics, LLC   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brisbane CA United States (2006)
Status: Acquired by Amgen (2022)

Organization Overview

First Clinical Trial
2010
NCT01257737
First Marketed Drug
2006
sodium phenylbutyrate (buphenyl)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

HORIZON THERAP | Horizon Therapeutics | HORIZON THERAPEUTICS IRELAND | Horizon Therapeutics Ireland DAC | Horizon Therapeutics, LLC | Horizon Therapeutics USA, Inc.

Active Ingredients

Marketed Drugs (3)

glycerol phenylbutyrate (ravicti) (2013)

sodium phenylbutyrate (buphenyl) (1996)

teprotumumab (2020)

Drugs in Phase 4 Trials (5)

glycerol phenylbutyrate (ravicti) (3 trials)

methotrexate (2 trials)

pegloticase (krystexxa) (3 trials)

sodium phenylbutyrate (buphenyl) (1 trial)

teprotumumab (3 trials)

Drugs in Phase 3 Trials (1)

Key: Horizon Therapeutics, LLC (0) Acquired (1)

inebilizumab (4 trials)

Drugs in Phase 2 Trials (5)

Key: Horizon Therapeutics, LLC (2) Acquired (3)

belatacept (nujolix) (1 trial)

daxdilimab (3 trials)

hzn-825 (3 trials)

medi7734 (3 trials)

vib4920 (4 trials)

Drugs in Phase 1 Trials (2)

Key: Horizon Therapeutics, LLC (0) Acquired (2)

vib1116 (1 trial)

vib9600 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 4)

Eye Diseases (Phase 4)

Gout (Phase 4)

Graves Ophthalmopathy (Phase 4)

Scleroderma, Diffuse (Phase 1)

Scleroderma, Systemic (Phase 1)

Sclerosis (Phase 1)

Thyroid Diseases (Phase 4)

Urea Cycle Disorders, Inborn (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 27
  • # of Trial APIs: 13